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Abstract 
Background: T2DM is a high-risk pregnancy with adverse fetal and maternal outcomes including repeated miscar-
riages and fetal malformations. Despite the established association between placental insufficiency and poor mater-
nal Th1-adaptability to the development of pregnancy complications in T2DM, there have been no established data 
to assess benefits of pre-pregnancy immunosuppression relative to gestational outcomes in T2DM. We hypothesized 
that pre-pregnancy macrolide immune suppression can re-establish normal placental development and uterine 
vascular adaptation in a mouse model of obesity-associated T2DM.
Methods: Fetal live birth rate, postnatal variability, mid-gestational uterine and umbilical flow dynamics and certain mor-
phological features of spiral artery modification were examined in the New Zealand Obese (NONcNZO10/Ltj) female mice 
(n = 56) weaned to ages of 32 weeks on a 60% calories/g high-fat diet (also referred to as HFD-dNONcNZO), and which 
received either tacrolimus (0.1 mg/kg s.c. q2d) , its vehicle (castor oil and ethanol) or metformin (in drinking water 200 mg/
dL p.o. ad libitum). HFD-BALBc-Rag2/IL2-gc female mice (n = 24) were used as HFD-immunodeficient controls.
Results: Treatment of the HFD-dNONcNZO female mice with tacrolimus improved live birth rates and postnatal 
viability scores (p < 0.01), normalized OGTT (p < 0.001), inhibited fetal malformation rates, restored morphology of 
spiral arterial modification; and improved uterine arterial and umbilical blood flow (p < 0.01). Placental production of 
TNFαand IL16 in the tacrolimus-treated HFD-dNONcNZO dams were restored to non-diabetic levels and the treat-
ment resulted in the inhibition of aberrant monocyte/macrophage activation during pregnancy in the HFD-dNONc-
NZO dams.
Conclusions: Our present data suggest a casual association between chronic maternal overnutrition and aberrancy 
in the maternal Th1-immune maladaptation to pregnancy and defective spiral artery modification, placental insuf-
ficiency and adverse fetal outcomes in the T2DM subjects. Further safety studies into the use of tacrolimus in the 
pre-pregnancy glycemic control may be beneficial.
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Background
Although pregnancy complicated by diabetes may result 
in a normal delivery with few adverse maternal effects or 
the child’s long-term health, obesity and poor glycemic 
control during pregnancy can have deleterious maternal 
and embryo-fetal effects as well as delivery complica-
tions [1]. Lifestyle choices, in particular caloric intake, 
contribute significantly to obesity and increase expres-
sion of pro-inflammatory markers that precede the 
onset of insulin resistance and hyperglycemia associated 
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in T2DM suggests that it may be a relevant therapeutic 
target [2], especially under physiological conditions such 
as gestation where adverse pregnancy outcomes (APOs) 
may occur in face of improper glycemic control.
Maintaining adequate glycemic control is the focus of 
current therapeutic interventions in pregnancies compli-
cated by gestational diabetes mellitus (GDM). However, 
lowering the risk of APOs has always been a challenge 
with the use of current therapeutic modalities such as 
insulin and/or metformin [3, 4]. Although insulin treat-
ment of GDM reduces serious perinatal morbidity and 
partially improves the woman’s health-related quality 
of life [5], nonetheless, offspring of obese and diabetic 
women with adequate symptomatic control of their 
hyperglycemia have a five to tenfold increased risk of 
congenital anomalies and a fivefold greater risk of peri-
natal mortality than non-obese women based upon the 
population studied [3, 4, 6].
When challenged with a high-fat diet, the New Zealand 
Obese (NONcNZO10/LtJ) mice become hyperglycemic, 
hyperinsulinemic and insulin resistant, making them an 
important tool for investigating the links between meta-
bolic dysregulation and reproductive and developmen-
tal defects in the obese and diabetic subjects [7, 8] and 
reviewed in [9].
While the use of immunosuppressants is primar-
ily indicated to prevent allograft rejection, mounting 
evidence suggests they may be used safely during preg-
nancy after solid organ transplant [10, 11]. A recent 
recommendation suggests that in utero exposure to the 
immunosuppressant tacrolimus does not increase the 
risk of major congenital malformations, although there 
was an increased risk of low birth weight and pre-term 
birth [12]. Based upon this safety profile and the clini-
cal importance of tacrolimus, it was decided to use this 
agent to test the hypothesis that immunosuppression can 
improve pregnancy outcomes in the chronically overfed 




All animal procedures were in accordance with the guide-
lines of Queen’s University Animal Care Committee. A 
total of fifty-six recombinant congenic NONcNZO10/
LtJ mice (also known as RCS-10 Strain, stock # 004456M) 
were purchased from the Jackson Laboratory (Bar Har-
bour, MA). Twenty-four alymphoid mice lacking T, B and 
NK cells with the genotype BALB/c-Rag2−/−Il2rg−/− (also 
referred to as Rag2−/−gc−/−) served as control cohorts in 
the high-fat diet (HFD) experiments, and twenty allowed 
ad  libitum access to a 20% fortified protein pellet diet 
(5K52 LabDiet® JL, St. Louis, MO) and were referred to 
as Normal-Fat Diet “NFD” fed mice. All alymphoid mice 
were bred in house and provided through the Queen’s 
University Animal Care Services. Mice were housed in 
decontaminated barrier facility and caged in pairs in ven-
tilated mouse cage racks. To avoid metabolomic incon-
sistencies [13], animal bedding consisted of recycled 
heat-treated hardwood Beta Chip® and cardboard paper 
bedding (NEPCO, Northeastern Product Corp., NY).
A 60% kCal high-fat diet (HFD) (D12492, Research 
Diets Inc., New Brunswick, NJ) was used to feed the 
NONcNZO10/LtJ mice and their respective control. For 
the specific purpose of this study and due to variability in 
disease penetrance, slower disease progression and high 
unpredictability of diabetes development in male NONc-
NZO10/LtJ mice [7], only female mice had longitudinal 
assessment of growth trajectory, glycemic control and 
reproductive outcomes. Details of the mouse models, 
therapeutic interventions, dietary and husbandry con-
ditions can be found in Additional file  1: Table S1. The 
temporal sequence of experimental procedures includ-
ing administration of high-fat diet, tacrolimus, and met-
formin are summarized in Additional file 1: Figure S1.
Preparation of pregnant mice
Allogeneic mouse pregnancies were obtained by mating 
females with males of the same mouse strain during week 
21 HFD which corresponds to week 26 of the mouse age 
using standard protocol [14]. Briefly, virgin female mice 
were placed in shoeboxes containing male bedding 48 h 
prior to cohabitation with males of the same strain, and 
vaginal plugs detected in the morning (07:00–08:00 a.m.) 
established GD 0.5 of pregnancy. Due to the current high 
rate of post-implantation loss in the HFD-dNONcNZO 
mice, pregnancies in GD 0.5 sperm-positive mice were 
verified using high-resolution ultrasound (Vevo 770; Vis-




An Ultra glucometer (Accu-Chek® Aviva/Roche Diag-
nostic, Montreal, QC) was used to monitor blood glucose 
of all mice through tail venipuncture once a week begin-
ning at 7  weeks of age until the time of euthanization. 
Single drops (~30 μL) of freshly obtained tail vein blood 
were sufficient to accurately measure blood glucose in all 
mice. Mice having non-fasting blood glucose concentra-
tions ≥14.49 mmol/L and/or impaired oral glucose tol-
erance test (OGTT) were considered diabetic and were 
annotated as HFD-dNONcNZO mice [7]. All HFD-
NONcNZO mice with non-fasting blood glucose of ≤6.4 
mmol/L were referred to as normoglycemic NONcNZO 
mice and were excluded from this study.
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Glucose tolerance test
To conduct the OGTT mice were first fasted for 6 h [15]. 
A 20% d-glucose (2 mg/g body weight) sterile syrup was 
administered by oral gavage using a 1  mL D29 gauge 
insulin syringe (Fisher Scientific Ltd., Montreal, QC) 
and blood glucose assessed at the following post-glucose 
challenge time points: 0, 15, 30, 45, 60, 90 and 120 min.
Test article and dose formulation
Due to the low bioavailability of tacrolimus (14–32%) 
[16] and data obtained in several pilot attempts at deter-
mining the optimum dosage of tacrolimus for use in this 
particular study, a modified tacrolimus-based monother-
apy protocol was developed for use in the HFD-dNONc-
NZO mice. Tacrolimus (FK506) (Tacrolimus-Astellas 
Pharma US, Inc., Deerfield, IL) was dissolved in castor 
oil and ethanol (vehicle for FK506 and untreated groups) 
and administered to the diabetic HFD-dNONcNZO mice 
on an alternate day regimen from week 16–19 and week 
25–29, respectively (Additional file  1: Figure S1, Table 
S1). For proper comparisons and adequacy in providing 
a standard diabetic drug-treated T2DM diabetic mouse 
cohort for this study, metformin (Metformin Hydro-
chloride (C4H12CIN5), Catalogue # M258815, Toronto 
Research Chemicals, Toronto, ON) was selected for 
use in HFD-dNONcNZO mice to generate genetically 
matched treated control. Due to the significant first pass 
effect, metformin doses in diabetic rodents are typi-
cally ≥50 mg/day [17]. Using this as a starting point and 
knowing that average water consumption in the diabetic 
mouse is ~10–15× the upper limit of normoglycemic 
mouse water consumption of 7.7 + 0.3 mL/30 g bwt [18], 
metformin was prepared fresh daily and made available 
ad libitum (200 mg/dL) per day.
Ultrasonography and determination of uterine arterial 
and umbilical blood flow
Transcutaneous Doppler ultrasonography was used to 
collect and analyze alterations to uterine arterial hemo-
dynamics and umbilical artery waveforms in isoflurane-
anesthetized virgin sperm-induced pregnancy (GD 
0.5–GD 18.5) among HFD-dNONcNZO and/or those 
receiving tacrolimus or metformin (n =  3 dams/group/
time point). A microultrasound biomicroscope (Vivo770, 
Visual Sonic Inc., Toronto, Ontario, Canada) and a 
30–40  mHz Real-Time Micro Visualization scanhead 
transducer operating at two frames per second (RMV704 
or 707B, VisualSonics Inc, Toronto, ON) were used in 
recording uterine arterial and umbilical artery blood flow 
using a previously described method for comparing pat-
terns of uterine and umbilical artery blood flow hemody-
namics [19]. Briefly, delivered by a well-fitted facemask, 
induction of anesthesia was initiated with 5% inhaled 
isoflurane in oxygen, and this was reduced to 1.5–2% to 
maintain unconsciousness. On average, the duration of 
sonography was 5–7 min. The sonographer was blinded 
to the treatment groups. With insonation angle of <45°, 
the Brightness mode (B-mode) Doppler and the high 
frame rate 707B 30  mHz scanhead were used to obtain 
pulse-wave Doppler (PWD) and record uterine arterial 
velocity waveforms for offline analysis. Recorded data 
included: velocities (cm/s; Peak systolic velocity-PSV, end 
diastolic velocity- EDV and time-averaged mean blood 
flow velocity-MV), and vascular indices (Pulsatility index 
(PI) and Resistivity index (RI) according to the equations 
PI  =  [PSV  −  EDV]/MV and RI  =  [PSV  −  EDV]/PSV, 
respectively. Since it has been observed that umbilical 
artery blood flow velocities are higher at the fetal than 
the placental end of the cord [20], and for the purpose of 
consistency in reporting, we strictly measured umbilical 
blood flow velocities from the placental end of the cord in 
all experimental groups. The software of the ultrasound 
machine automatically calculated arterial hemodynamic 
data after manual or automatic delineation of the Dop-
pler waveforms. Mean values of the hemodynamic data 
were established by averaging a minimum of five Dop-
pler waveforms at each time point. Finally, the following 
parameters were implemented in the B-mode recording: 
the lowest high-pass filter level used was 100 Hz, 2000 ms 
display window, Doppler gain of 5.00 dB, the pulsed rep-
etition frequency was between 4 and 48 kHz and was set 
to detect low and high blood flow velocities, respectively.
Fetal analysis and tissue preparation
Anesthetized (ketamine–xylazine) pregnant mice were 
euthanized on the mornings of GD18 by cardiac punc-
ture with the heart cut between 09:00 and 11:00  a.m. 
After performing Cesarean section, the litter size was 
counted in combination with their location along the 
length of the respective uterine horn. Both uterine horns 
were examined for the presence of early and late resorp-
tions. Viable fetuses were identified by virtue of their 
ability to move and breathe, weighed and examined for 
gender and fresh gross anomalies [21]. After removal 
of all membranes from the nose and mouth, the viable 
fetuses were placed in a 37.5  °C incubator for 1 h, after 
which the viability of each pup was reassessed. Thereaf-
ter, all fetuses that were in the incubator were euthanized 
and examined for visceral anomalies [21]. Placentas from 
viable fetuses were weighed and immediately fixed in an 
alcoholic paraformaldehyde solution (2% wt:vol in 70% 
ethanol). Skeletons were stained using Alcian Blue and 
Alizerin Red double staining technique [22]. The Inter-
national Federation of Teratology Societies (IFTS) glos-
sary [23] nomenclature for description of developmental 
anomalies was adapted in this report. Hematoxylin and 
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Eosin stained, paraffin-wax embedded placental sections 
were prepared according to standard protocol [24]. His-
tological examination of placental sections and calcula-
tion of spiral artery wall/lumen ratio were performed by 
two histologists blinded to the treatment methods.
Statistical analysis
Data were analyzed with Sigmaplot (Systat Software, 
Inc., San Jose, CA) and Graph-Pad Prism 6 software. 
Normal distributions were validated using the Kolmogo-
rov–Smirnov method. Parameters of normally distrib-
uted data were expressed, unless otherwise indicated, as 
mean ±  SEM or as mean ±  SD using appropriate non-
parametric procedures (Fisher Exact test; Kruskal–Wal-
lis and/or one-way ANOVA with interaction effects) 
followed by Dunn’s multiple comparison test or Mann–
Whitney U test or Miller’s procedure for pairwise com-
parisons of independent parameters. Two-way ANOVA 
comparing treatment groups with their untreated 
diabetic or normoglycemic control was also used to 
determine p values for the source of variation across 
treatments. Linear (parametric) data were assessed by 
Pearson correlation, whereas nonlinear (non-parametric) 
data were assessed by Spearman correlation. Glucose tol-
erance graphs were generated by plotting the recorded 
glucose data per mouse per minute collection time. One 
way analysis of variance (ANOVA) followed by Student t 
test was performed to determine alpha values for statisti-
cal differences among mean blood glucose values across 
experimental mouse groups. Due to lack of linearity in 
the declining glucose concentrations over time during 
the OGTT, the area under the curve (AUC) measured in 
the log-linear interpolation method [25] made use of the 
log average of Δ time interval according to the equation 
Area log = (C1 − C2)/(log C1 − log C2)*Δ time. A proba-
bility value of p ≤ 0.05 was considered statistically signifi-




Tacrolimus and glucose tolerance in the HFD‑dNONcNZO 
mice
After 7  weeks of the HFD, the HFD-dNONcNZO mice 
developed impaired glucose tolerance which required 4 
consecutive weeks of therapeutic intervention with tac-
rolimus (0.1 mg/kg) to restore proper glycemic response 
at OGTT as shown in Fig. 1A–C. Therefore, tacrolimus 
was administered in two consecutive therapeutic inter-
ventions, each of 4  weeks in duration for the period 
spanning HFD weeks 15–18 and HFD weeks 25–28, 
respectively. This significantly improved glucose tol-
erance as shown in Fig.  1D–F, and lowered the AUC 
glucose in OGTT in a time-dependant manner (Addi-
tional file  1: Figure S2A–C). Treated groups only had 
moderate hyperglycemia detected during mid-gestation 
at GD10.5 (9.36 ± 0.88 tacrolimus vs 8.08 ± 0.76 mmol/L 
metformin) as opposed to the significant hyperglycemia 
observed in untreated diabetic HFD-dNONcNZO dams 
(18.53 ± 0.58 mmol/L) (p < 0.001). However, except for 
some subtle differences between the metformin- and the 
tacrolimus-treated and their corresponding untreated 
HFD-dNONcNZO dams, lower blood glucose values 
were detected at necropsy at GD 18.5 among the tacroli-
mus-treated mouse cohorts (Table 1). 
Tacrolimus protects against fetal demise and reproductive 
health adversities in the HFD‑dNONcNZO dams
The higher maternal weights (Table 1), elevated non-fast-
ing glucose levels and impaired OGTT in the untreated 
HFD-dNONcNZO dams translated to poorer pregnancy 
and progeny outcomes compared to the treated HFD-
dNONcNZO groups receiving either tacrolimus or met-
formin. Reduced implants was a characteristic feature of 
APOs with fewer implants per litter in untreated HFD-
dNONcNZO (5.25 ± 1.71 implants/dam) as opposed to 
the tacrolimus-treated dams (8.67 ± 0.58 and 7.13 ± 1.53 
implants/dam) or those receiving metformin (9.0 ± 2.05 
implants/dam), (Table  1). In addition, the numbers of 
viable fetuses per litter and individual fetal birth weight 
were also significantly reduced in untreated dams 
(Table 1: compare 2.5 ± 1.29 vs 7.67 ± 1.53, 6.33 ± 1.53 
or 7.00 ± 1.00) and Fig. 2a–d. Viable fetuses at the time 
of necropsy, expressed as a percent total fetuses per lit-
ter was also significantly reduced in untreated dams 
(33.0  ±  19.1) when compared to those treated with 
tacrolimus (0.05 or 0.1  mg/kg) or metformin (Table  1: 
96.3  ±  7.78 and 93.3  ±  11.5 in the tacrolimus-treated 
and 82.0 ± 40.1 in the metformin-treated dams). Indeed, 
whereas between 80 and 89% of the fetuses were still 
viable 1 h post necropsy in the treated groups (Fig. 2d), 
fetal viability among HFD-dNONcNZO dams was less 
than 20% at necropsy at GD 18.5 (Fig. 2d), and none of 
the HFD-dNONcNZO progeny was viable 1  h post-
necropsy. The resorption rate, when calculated as a 
percent total implants per litter and percentage of fetal 
demise at GD 18.5 among untreated dams were signifi-
cantly elevated in the HFD-dNONcNZO mice (Table  1: 
compare 55.0  ±  10.6 vs 16.5  ±  19.1, 16.7  ±  6.5 or 
18.7 ± 23.5) (see also Fig. 2e). The Placentas from HFD-
dNONcNZO dams were heaviest, whereas the lowest 
placental weights came from low-dose tacrolimus- and 
metformin-treated dams. Although the higher fetal/pla-
cental (F/P) weight ratio in the treated groups (Fig.  2f ) 
was indicative of better in utero fetal health, nonetheless, 
fetal body weights followed a similar trend, but unlike the 
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placental findings these trends were not statistically sig-
nificant (p ≥ 0.07). Finally, contrasting the human stud-
ies in which the rate of neonatal hypoglycemia among 
women with elevated BMI were 3% [26], fetal blood glu-
cose at necropsy in the present study was found to be 
significantly elevated in the untreated HFD-dNONcNZO 
dams (6.69 ± 0.41 mmol/L) (Fig. 2g). Normal values were 
detected in the treated groups irrespective of the treat-
ment modality (3.15 ±  0.27  mmol/L in the tacrolimus-
treated vs 3.56 ± 0.36 mmol/L in the metformin-treated 
dams) (Fig. 2g).
Tacrolimus‑mediated prevention of fetal demise is 
mechanistically linked to restored uterine artery 
physiology and umbilical flow during gestation in treated 
HFD‑dNONcNZO mice
Maternal adaptation to pregnancy in the tacrolimus-
treated HFD-dNONcNZO dams was further assessed 
to examine aspects of uterine (Ut. Art.) and umbilical 
artery flow dynamics during gestation using Doppler 
ultrasonography during early and late-mid gestation. 
As shown in Fig.  3, representative ultrasound B-mode 
(UBM) images of the right uterine artery proximal to the 
Fig. 1 Tacrolimus restored glucose tolerance in the chronically overfed HFD-dNONcNZO dams. A–C Oral glucose tolerance test (OGTT) performed 
prior to treatment with tacrolimus (A) and after 2 weeks (B) or 4 weeks (c) of tacrolimus (0.1 mg/kg). D–F Effect of HFD chronicity and glycemic 
response to metformin or tacrolimus in the HFD-dNONcNZO mice chronically fed with 60% kcal % HFD for 7 weeks (D), 15 weeks (E) or 25 consecu-
tive weeks (F), respectively. Representative OGTTs were from two sets of experiments (n = 5–8/group) analyzed with one-way ANOVA followed by 
Dunn’s multiple post hoc test comparing treated mice to HFD-dNONcNZO
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conceptus assessed at GD10.5 in an HFD-dNONcNZO 
dam (Fig.  3a, b) reveals consistent pattern of uterine 
artery insufficiency in the untreated dams as indicated 
by the UBM waveform and low peak systolic and end-
diastolic flow velocities compared to those receiving met-
formin (Fig.  3c) or tacrolimus (Fig.  3d). Indeed, rescued 
Ut. Art. flow in the tacrolimus- or metformin-treated 
dams resulted in restored vascular pulsatility through-
out gestation and at specific phases of pregnancy in 
treated dams as shown in Fig.  3e (comparing all experi-
mental groups). Noticeably, similar to findings previously 
described [19], Ut. Art. PI segregated into phases corre-
sponding to fluctuations in the normoglycemic mouse 
pregnancy and associated embryonic/fetal and maternal 
events, with phases 1, 2 depicting normal peri-implanta-
tion events, phases 3, 4 were the outcome of the placen-
tation process and phases 5, 6 reflective of progressive 
fetal growth-associated vascular events. Additionally, 
microultrasonographic examination of fetuses belong-
ing to the HFD-dNONcNZO dams revealed features of 
in utero fetal distress. Among the latter were the signifi-
cantly restricted Ut.Art. flow (40.51 ±  2.73 mm/s in the 
HFD-dNONcNZO dams vs 125.14  ±  8.68  mm/s in the 
tacrolimus-treated and 97.13  ±  6.43  mm/s in the met-
formin-treated dams, respectively) (Fig. 3f ), and features 
of cardiac dysrhythmias such as bradycardia detected in 
fetuses of untreated dams (Fig. 3g, and compare Fig. 3h–j, 
respectively). Interestingly, percentage of fetal demise was 
positively correlated with increased Ut. Art. resistivity 
during mid-late gestation in the untreated HFD-dNONc-
NZO dams (Pearson Correlation Coefficient = 0.65, with 
p < 0.01 when compared to the treated) (Fig. 3k).
Protection against fetal demise in the tacrolimus‑ 
and metformin‑treated HFD‑dNONcNZO dams is linked 
to proper spiral artery (SA) remodeling
Histopathological analysis of SA remodeling at GD10.5 
revealed restricted process in the HFD-dNONcNZO 
dams as measured in their significantly higher wall: 
lumen ratio (Fig.  4a, b), narrower lumen (Fig.  4c) and 
thicker SA walls (Fig.  4d) when compared to treated 
dams or their normative controls. A significant direct 
casual association between % fetal demise as a selected 
APO and improper SA remodeling (Pearson Correlation 
Fig. 2 Low fetal viability and high rate of fetal demise were characteristics of pregnancy in the HFD-dNONcNZO dams. a–c Findings at necropsy at 
gd18.5 for the common gross manifestations of GDM among the HFD-dNONcNZO dams typically expressing low fetal viability and higher rates of 
fetal resorption. Notwithstanding its effect on birth weight, treatment with tacrolimus enhanced live birth rate (d), lowered percentage of demise 
(e) and enhanced fetal/placental (F/P) weight ratio (f). Reference values for random blood glucose were also detected among pups delivered to 
tacrolimus-treated dams (g). n = a minimum of 7 dams/group with variable numbers of fetuses/pups examined. p < 0.001 in d
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Coefficient = 0.76 with p < 0.01 compared to untreated) 
was detected in the untreated HFD-dNONcNZO dams 
(Fig. 4e) suggesting a link between poor uterine arterial 
physiology and progeny outcomes in these mice.
Tacrolimus and fetal parameters in treated 
HFD‑dNONcNZO mice
External gross and skeletal malformations
Since high-fat diet (45% kCal fat) alters fetal growth and 
inhibits murine fetal bone development [27], we exam-
ined external and skeletal growth characteristics of 
fetuses delivered to HFD-dNONcNZO mice and those 
receiving metformin or tacrolimus. Due to the extremely 
low viability of offspring from HFD-dNONcNZO mice 
(n  =  3), the external morphology was assessed in all 
fetuses (n  =  10). The cumulative external malforma-
tion rate in the HFD-dNONcNZO offspring was 90% 
(Additional file  1: Table S2). Offspring from tacroli-
mus (0.05 or 0.1  mg/kg) and metformin treated mice 
had malformation rates of 5, 5.3 and 12%, respectively. 
Craniofacial defects were most prevalent and included 
in descending order of prevalence: anophthalmia, exen-
cephaly, and protruding tongue. The midline defect, 
omphalocele was also noted in the HFD-dNONcNZO 
fetuses (Fig. 5).
In assessing skeletal malformations only three fetuses 
were viable in all the HFD-dNONcNZO mice examined. 
One litter suffered a processing error and thus was not 
assessed. When exposed to tacrolimus or metformin, 
HFD-dNONcNZO mice displayed skeletal malforma-
tions, variations and ossification delays, but no pattern 
emerged (Table 2). The common malformation was mis-
aligned sterna with an increased incidence in the num-
ber of fetuses with supernumerary ribs (a variation not a 
Fig. 3 Tacrolimus-mediated inhibition of fetal demise is linked to restored uterine and umbilical artery flow during pregnancy. a–d Representative 
UBM image of the right uterine artery proximal to the conceptus being assessed at gd10.5 (a) and that of an Ut. Art. PWD in an HFD-dNONcNZO 
(b), tacrolimus-treated (c) or metformin-treated (d) (long red arrow peak systolic velocity, short red arrow end diastolic velocity). A significant reduc-
tion in the uterine artery blood flow was detected in the HFD-dNONcNZO dams between gd10.5-gd18.5 (e). f Group scatter-graphs of the peak 
umbilical arterial flow depicting impact of HFD and effect of treatment with metformin or tacrolimus in rescuing umbilical arterial flow in treated 
dams. g A representative UBM image taken from gd14.5 fetus and representative PWD for the most common differences in the umbilical artery 
peak flow velocity and waveform from HFD-dNONcNZO (h), metformin (i) or tacrolimus-treated dams (j). k A significant association between  % 
fetal demise and increased Ut. Art. resistivity during mid-late gestation was demonstrable in the HFD-dNONcNZO dams (k) (*p < 0.01). Note the 
significant increase in the umbilical arterial blood flow in the tacrolimus-treated dams over those receiving metformin (200 mg/dL) (**p < 0.01) (e). 
n = 7 dams/group and two experimental repeats with 34–39 pups examined in utero, p < 0.001 at 95% confidence
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malformation; 14 instead of 13 ribs) and delayed ossifica-
tion primarily in the distal limbs (Fig. 6).
Internal malformations
Internal examinations were only conducted on fetuses 
that were viable at the time of Cesarean section. Thus, 
only three HFD-dNONcNZO fetuses were examined, but 
each presented with multiple anomalies while the inci-
dences of malformations in low-, high dose tacrolimus 
and metformin treated were 13.6, 11 and 5.9%, respec-
tively (Additional file  1: Table S3). Anomalies included 
hydroureter, hydronephrosis, hydrocephalus, outflow 
tract anomalies and interventricular septal defect. Vari-
ations such as absent gallbladder, and deficient lobe 
number in right lung were also noted in the HFD-
dNONcNZO offspring, but not the other groups (Addi-
tional file 1: Table S3).
Discussion
The present study demonstrates that tacrolimus, an 
immunosuppressant currently used in organ transplant 
procedures, significantly improved glycemic control with 
concomitant improvement of reproductive outcomes, 
and increased postnatal survival without increasing risks 
of major congenital malformations in a murine model 
of human obesity-associated T2DM. In insulin resistant 
diabetic HFD-dNONcNZO mice, metformin normal-
ized blood glucose levels to the same extent as tacrolimus 
but did not offer the same degree of protection against 
reproductive health and developmental adversities. This 
suggests that the immune system, independent of glyce-
mic control, is a critical component of the management 
of adverse pregnancy outcomes associated with chronic 
maternal overnutrition.
Carrying a pregnancy after solid organ transplantation 
is considered a high risk for maternal, fetal and neona-
tal complications but has been successful. Multiple stud-
ies have demonstrated that clinically tacrolimus poses 
no increased risk of congenital malformations but may 
increase the incidence of low birth weight and pre-term 
delivery [10, 11, 28, 29]. These clinical experiences were 
in conflict, to some extent, with the preclinical safety 
studies conducted in female rats dosed prior to mating 
or during organogenesis [30, 31]. At a dose one-third of 
the maternally toxic dose based upon exposure, tacroli-
mus had adverse effects on female reproductive param-
eters causing embryolethality and significant reductions 
of pup weights [30]. These observations resulted in a US 
FDA pregnancy class C which states that “Animal repro-
duction studies have shown an adverse effect on the fetus 
Fig. 4 Low percentage of fetal demise in the tacrolimus-treated HFD-dNONcNZO dams is linked in part to restored spiral artery (SA) remodeling 
during gestation. a Representative spiral artery histopathological analysis at gd10.5 revealing restricted remodeling of these structures in the HFD-
dNONcNZO dams as measured in their significantly higher wall:lumen ratio (b), narrower lumen (c) and thicker SA walls (d). Direct causal relation-
ship existed between  % FGR and restricted SA W:L ratio at gd10.5 in the HFD-dNONcNZO dams (e). N = a minimum of 7 dams/group and two 
experimental repeats, *p < 0.01 at 95% confidence
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and there are no adequate and well-controlled studies in 
humans, but potential benefits may warrant use of the 
drug in pregnant women despite potential risks”. However, 
in over 200 exposed pregnancies and 236 babies born to 
organ transplant recipients where tacrolimus was admin-
istered as a multi-drug based therapy, no significant 
teratogenicity could be concluded from multiple clinical 
registries [32–35]. Nonetheless, unlike the present study, 
preclinical safety reports in rats were in contradiction 
to each other. Saegusa and associates [30] reported on 
reduced reproductive performance, increased embryole-
thality and decreased pup weights among pregnant rats 
orally receiving 1.0 and 3.2  mg/kg FK506 (tacrolimus) 
after organogenesis and during lactation [30]. On the 
other hand, Farley and co-workers [31] recounted nor-
mal maternal health but dose-dependant elevation in the 
Fig. 5 External features characteristics of HFD-dNONcNZO fetuses at the time of Caesarean section at GD 18.5. Although normal craniofacial and 
midline phenotypes were seen in less than 10% of the cases such as those in a and e respectively, microphthalmia (micro) in b, protruding tongue 
(pt), anophthalmia (an) and exencephaly (ex) in c, swollen forebrain (sfb) and open eye (oe) in d, and omphalocele (omph) in f were the most 
frequent defects in the offspring of diabetic HFD-dNONcNZO dams
Table 2 Summary of the major skeletal malformations, variations and delayed ossifications in fetuses examined
Skeletons of viable fetuses were double-stained with Alcian blue and Alizarin red and assessed for malformations, variations and ossification delays. The incidences 
are reported in percentages with the values in parentheses reflecting the number of litters affected
a Litters were all resorbed or dead. Therefore no visceral or skeletal examinations were done on them (only external examination because the numbers of pups was so 
low)
HFD‑dNONcNZO Tacrolimus (0.05 mg/kg) Tacrolimus (0.1 mg/kg) Metformin (200 mg/dL)
Fetuses (litters) 3 (3) 22 (3) 18 (3) 17 (3)
14 ribs 33% (1) 27% (3) 44% (3) 18% (2)
Incomplete ossification
 Sternebra a 0% 0% 6% (1)
 Metacarpals a 0% 0% 6% (1)
 Forelimb phalanges 33% (1) 0% 6% (1) 12% (2)
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percentages of post-implantation resorption that led to 
the conclusion of a relative safety to the use of tacrolimus 
in pregnancy [31]. Similarly, Ramos et  al. [36] reported 
on normal maternal and fetal health in otherwise normo-
glycemic female Wistar rats orally receiving tacrolimus 
at 10–40 times the currently described dosage. Notwith-
standing species and route of administration related-
differences in interpreting tacrolimus pharmacokinetics 
among mice, rats and women, our data are generally sup-
portive of previous reports from clinical registry leverag-
ing records from 20 to 200 women receiving 0.1–0.4 mg/
kg/day tacrolimus mono-therapy or in a combination of 
immunosuppression whereby higher fetal exposure ratios 
were found to be exponentially related to higher mater-
nal trough blood concentrations of the compound but 
reported on normal birth weights and post-natal devel-
opment in these pregnancies [28, 35, 37–39]. This is an 
important consideration because tacrolimus, like most 
drugs, crosses the placenta with concentrations found 
in the cord blood being ~71, 23 and 19% of maternal 
concentrations for whole blood, plasma and unbound 
form, respectively [28, 39]. Even with transfer across 
the placenta, tacrolimus neither causes gross congenital 
malformations in humans [10, 32, 40, 41] nor does it in 
normoglycemic Wistar rats exposed for 15 days to about 
10–40× the current dose per oral during peri-implan-
tation phase [36]. Nevertheless, tacrolimus has been 
reported to cause transient and reversible materno-fetal 
comorbidities such as hyperkalemia and in some cases 
reduced renal mass (oligonephronia) thereby increasing 
Fig. 6 Representative depictions of common skeletal malformations and variations. Photomicrographs a, b illustrate, respectively, normal and 
misaligned ossification centers of the sternum (arrowhead). c Depicts ossification of the metacarpals (met) and phalanges (phal) in the forepaw, 
with delayed ossification of the proximal ( ), intermediate ( ) and distal ( ) phalanges shown in d, respectively. Ribs 12 and 13 are identified in 
e (arrows) with an additional 14th rib identified in f (arrows)
Page 12 of 15Albaghdadi et al. J Transl Med  (2017) 15:32 
the risk for further development of renal failure and 
hypertension in adult life [40, 42]. Additionally, it should 
be pointed out that although the present study used tac-
rolimus to normalize glycemic control in the obese and 
T2DM mice, a paradoxical new-onset diabetes after 
transplantation (NODAT), a severe complication follow-
ing organ transplantation, has been reported to occur 
in between 2 and 53% of transplanted patients receiving 
higher dosing of tacrolimus and/or having pretransplan-
tation hyperglycemia (reviewed in [43–45]. Nonethe-
less, NODAT has not been reported in recent studies on 
allogeneic uterine transplantation in rats receiving low 
dosing of tacrolimus [46], neither was it associated with 
worsening of clinical outcomes during a mean follow-up 
of 3 years in kidney transplant recipients [47]; neverthe-
less it is warranted that further pre-clinical safety studies 
on the potential use of tacrolimus as anti-diabetic agent 
should be conducted.
Among endometrial changes and mechanisms linked 
to the adverse pregnancy outcomes in diabetic mice 
and women are impaired spiral artery remodeling and 
trophoblast invasion defects during gestation [48, 49]. 
In an attempt to elucidate how tacrolimus restored vas-
cular adaptation to pregnancy in the obese and diabetic 
mice, we examined uterine arterial physiology, spiral 
artery remodeling and late gestational (GD 18.5) placen-
tal cytokines during pregnancy in the HFD-dNONcNZO 
dams. Incomplete spiral artery remodeling with lumen 
stenosis has been recognized among ominous patho-
physiological signs of poor placentation in GDM [50, 
51], This heralding histopathological sign was evident 
in the placentas of HFD-dNONcNZO dams expressing 
higher levels of pro-inflammatory cytokines that include 
TNFα, IL16 and IL23 (Additional file  1: Table S4). This 
is consistent with the reported human and non-human 
primate data that the placenta develops exaggerated pro-
inflammatory response to obesity, which contributes to 
or results from placental vascular insufficiency [52, 53]. 
Therefore, important implications came from findings 
of restricted uterine artery pulsatility and poor umbilical 
flow dynamics during gestation in the HFD-dNONcNZO 
dams. Vascular indices (RI and/or PI) are used to inves-
tigate impedance of the vascular bed distal to the vessel 
being examined, and a large quantity of continuous for-
ward flow is generally observed throughout the diastole 
in low-resistance arterial waveforms [54]. Contrary to 
this, higher vascular indices are characteristics of vas-
cular flow supplying high-resistance and leaky vascular 
beds [54]. Through mechanisms linked to chronic sys-
temic hyperglycemia, local inflammation and the release 
of pro-inflammatory and pro-angiogenic molecules such 
as vascular endothelial growth factor (VEGF), advanced 
glycation end-products (AGE) and alterations to de novo 
synthesis of nitric oxide (NO), maternal hyperglycemia 
is known to induce vascular defects characterized by 
increased angiogenesis, increased vascular resistance, 
hyper-coagulability and preponderance of highly per-
meable vessels [55–59]. On the other hand, it has been 
shown that umbilical artery flow velocity negatively cor-
relates with umbilical artery resistance and is reflective of 
alterations to the uterine artery PI and placental vascular 
resistance [60]. Therefore, the overall lower uterine artery 
PI throughout gestation and higher RI in the untreated 
HFD-dNONcNZO dams dictates their poor breeding 
performance and the higher rates of inflammation-medi-
ated fetal demise observed in this mouse model. Also, 
considering that the placenta is an organ requiring con-
stant perfusion and has low vascular indices with uter-
ine artery PI values decreasing with gestational age [61], 
the present findings that therapeutic interventions with 
either tacrolimus or metformin normalized uterine artery 
PI in the treated HFD-dNONcNZO dams have clinical 
inferences suggestive of a pivotal role for adequate mater-
nal glycemic control and immuno-modulation relative to 
pregnancy outcomes in conditions of chronic maternal 
overnutrition.
Taken together, the present study support the obser-
vation that adverse fetal health among neonates born 
to diabetic mothers cannot be explained solely on the 
basis of maternal hyperglycemic control [62]. Our data 
are also in parallel with the notions made by Leach et al. 
and Ericsson et  al. that hyperglycemia should only be 
seen as a player within a spectrum of diabetic compli-
cations whereby maternal inflammation might have the 
upper hand [62, 63]. Nonetheless, the present data are 
in conflict with the primate studies reported by Frias 
and associates [52] where in the relatively wider pla-
centa exchange area and high functional reserve are to 
be blamed for the lower rates of fetal growth restriction 
reported in the primate studies. However, the high rate 
of fetal demise at necropsy reported in the present study 
and by Frias and associates points to the uteroplacental 
flow restriction and inflammation to be the plausible cul-
prits. Indeed, similar to the non-human primate model 
of obesity-induced placental growth restriction [52], our 
findings suggest that inflammation in the pregnant adult 
HFD-dNONcNZO female mice is likely localized in tis-
sues involving at least the placenta. This supports pre-
vious studies in that the end-organ response to HFD is 
local yet associated with dysregulation of metabolic, vas-
cular and inflammatory pathways requiring an immuno-
suppression [64].
A limitation of the present study is the chance of inves-
tigating renal functions among the tacrolimus-treated 
HFD-dNONcNZO dams. It has been reported in ordi-
nary kibble-fed male Wistar rats that tacrolimus at a dose 
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of 0.6 mg/kg/day for 9 consecutive weeks is nephrotoxic 
[65]. Important to tacrolimus pharmacokinetics and 
mechanism of action is its bioavailability and the ratio 
of bound:free form in the blood. The latter two maternal 
variables are greatly influenced by a multitude of factors 
among which the renal functions have long been rec-
ognized [66]. Therefore, future studies are warranted to 
establish whether or not our treated mice suffered tac-
rolimus-related nephrotoxicity. A possibility to overcome 
this limitation is the titration of dosage to maintain whole 
blood tacrolimus trough concentrations in the usual ther-
apeutic range in plasma or urine of treated dams. This is 
particularly important since tacrolimus pharmacokinetic 
changes during pregnancy with maternal factors such as 
anemia and hypoalbuminemia significantly contribute to 
at risk pregnancy.
Conclusions
Our data suggest a casual association between chronic 
maternal overnutrition and the development of 
materno-fetal comorbidities manifested in the immune-
mediated glucose intolerance, defective spiral artery 
modification, placental insufficiency and adverse fetal 
outcomes in a mouse model of human obesity-associ-
ated T2DM. We have specifically found that the use of 
tacrolimus at the dose of 0.1 mg/kg q2d is adequate in 
restoring glucose homeostasis prior to and during ges-
tation in the obese and diabetic subjects. The weight 
of evidence from pregnancies following solid organ 
transplant points to a marginal embryo-fetal safety of 
in utero tacrolimus exposure. On the other hand, met-
formin normalized glucose intolerance in HFD-
dNONcNZO mice but offered less protection against 
diabetes-induced embryopathies than tacrolimus. This 
suggests that the etiology, incidence and severity of 
diabetes-associated congenital anomalies may have 
an immunological component requiring appropriate 
immuno-therapeutic intervention.
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